T cell-eosinophil crosstalk—A new road for effective immune checkpoint blockade in breast cancer?

Sharon Grisaru-Tal; Ariel Munitz

doi:10.1016/j.ccell.2022.11.008

T cell-eosinophil crosstalk—A new road for effective immune checkpoint blockade in breast cancer?

Sharon Grisaru-Tal, Ariel Munitz^*

^*Corresponding author for this work

Clinical Microbiology and Immunology

Research output: Contribution to journal › Comment/debate

Abstract

Immune checkpoint blockade (ICB) has revolutionized the landscape of cancer treatment. Nevertheless, most cancer patients still do not respond to ICB. In this issue of Cancer Cell, Blomberg et al. illustrate a critical cooperation between T cells and eosinophils, which jointly enhance effectiveness of ICB in breast cancer.

Original language	English
Pages (from-to)	9-11
Number of pages	3
Journal	Cancer Cell
Volume	41
Issue number	1
DOIs	https://doi.org/10.1016/j.ccell.2022.11.008
State	Published - 9 Jan 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ccell.2022.11.008

Cite this

@article{c8dad50481f24dcb84668b7f704875ec,

title = "T cell-eosinophil crosstalk—A new road for effective immune checkpoint blockade in breast cancer?",

abstract = "Immune checkpoint blockade (ICB) has revolutionized the landscape of cancer treatment. Nevertheless, most cancer patients still do not respond to ICB. In this issue of Cancer Cell, Blomberg et al. illustrate a critical cooperation between T cells and eosinophils, which jointly enhance effectiveness of ICB in breast cancer.",

author = "Sharon Grisaru-Tal and Ariel Munitz",

note = "Publisher Copyright: {\textcopyright} 2022 Elsevier Inc.",

year = "2023",

month = jan,

day = "9",

doi = "10.1016/j.ccell.2022.11.008",

language = "אנגלית",

volume = "41",

pages = "9--11",

journal = "Cancer Cell",

issn = "1535-6108",